BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress

Jun 27, 2017

Oral Presentation to Include Interim Results from its Ongoing Phase 1/2 BMN 270 Clinical Program, a Gene Therapy for Hemophilia A.

Conference call and web-cast to be held July 11th at 2:30pm CEST/8:30am ET